Yahoo! Sports

Forxiga™ (dapagliflozin), First-In-Class SGLT2 That Works Independently of Insulin, Now Approved in

PRINCETON, N.J. and LONDON--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYS: BMY) and AstraZeneca (NYS: AZN) today announced that the European Commission has approved Forxiga ™ (dapagliflozin) ...
Business Wire

Forxiga™ (dapagliflozin), First-In-Class SGLT2 That Works Independently of Insulin, Now Approved in European Union for Treatment of Type 2 Diabetes

Forxiga, a once-daily oral agent, provides physicians with a new option to improve glycaemic control as monotherapy in metformin-intolerant patients or combination therapy Reduction of weight and ...
FierceBiotech

FORXIGA™ (dapagliflozin) now approved in European Union for treatment of type 2 diabetes

AstraZeneca and Bristol-Myers Squibb Company today announced that the European Commission has approved FORXIGA™ (dapagliflozin) tablets for the treatment of type 2 diabetes in the European Union (EU).
Nasdaq

AstraZeneca Announces Approval Of Forxiga In Japan For Chronic Heart Failure

(RTTNews) - AstraZeneca Plc (AZN.L, AZN) announced the company's Forxiga has been approved in Japan for the treatment of patients with chronic heart failure who are receiving standard of care. The ...